By Josh Beckerman
Renovaro shares declined after the company said it received an email from Predictive Oncology terminating an agreement to be sold to Renovaro.
The stock fell 16% to 39 cents in the regular session Friday. It was up 5% to 41 cents after hours.
"Renovaro's position is that POI must comply with the binding obligations thereunder and enter into an exclusive license agreement as required in each of the binding agreements," the company said. It believes Predictive Oncology is in breach of the binding agreements.
A representative for Predictive Oncology didn't immediately reply to a request for comment.
Renovaro focuses on diagnostics, drug discovery and genetically enhanced cancer therapies.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
April 04, 2025 18:45 ET (22:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。